Suchergebnisse - "O'Donnell, Peter H"

PubPharm (13)

1

Phase II Trial of Olaparib in Patients With Metastatic Urothelial Cancer Harboring DNA Damage Response Gene Alterations

enthalten in: JCO precision oncology | 2023

von Doroshow, D. | O'Donnell, P. | Hoffman-Censits, J. | +8

CommentIn: JCO Precis Oncol. 2023 Aug;7:e2300293. - PMID 37535882

2

Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV‑201) : a multicentre, single-arm, phase 2 trial

enthalten in: The Lancet. Oncology | 2021

von Yu, E. | Petrylak, D. | O'Donnell, P. | +17

CommentIn: Lancet Oncol. 2021 Jun;22(6):748-749. - PMID 33991513

3

Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010) : a multicentre, open-label, randomised, phase 3 trial

enthalten in: The Lancet. Oncology | 2021

von Bellmunt, J. | Hussain, M. | Gschwend, J. | +24

CommentIn: Lancet Oncol. 2021 Jun;22(6):e236. - PMID 34087145

4

Long-Term Outcomes in KEYNOTE-052 : Phase II Study Investigating First-Line Pembrolizumab in Cisplatin-Ineligible Patients With Locally Advanced or Metastatic Urothelial Cancer

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2020

von Vuky, J. | Balar, A. | Castellano, D. | +13

5

Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2019

von Rosenberg, J. | O'Donnell, P. | Balar, A. | +10

CommentIn: J Clin Oncol. 2019 Oct 10;37(29):2587-2591. - PMID 31260641

6

Mocetinostat for patients with previously treated, locally advanced/metastatic urothelial carcinoma and inactivating alterations of acetyltransferase genes

enthalten in: Cancer | 2019

von Grivas, P. | Mortazavi, A. | Picus, J. | +16

7

First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052) : a multicentre, single-arm, phase 2 study

enthalten in: The Lancet. Oncology | 2017

von Balar, A. | Castellano, D. | O'Donnell, P. | +12

CommentIn: Lancet Oncol. 2017 Nov;18(11):1428-1430. - PMID 28967486

8

Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma : Updated Results From a Phase 1/2 Open-label Study

enthalten in: JAMA oncology | 2017

von Powles, T. | O'Donnell, P. | Massard, C. | +16

CommentIn: J Urol. 2018 May;199(5):1110-1112. - PMID 29677898

9

Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012) : a non-randomised, open-label, phase 1b study

enthalten in: The Lancet. Oncology | 2017

von Plimack, E. | Bellmunt, J. | Gupta, S. | +7

CommentIn: Lancet Oncol. 2017 Feb;18(2):160-161. - PMID 28081913

10

Clinical Evaluation of Cisplatin Sensitivity of Germline Polymorphisms in Neoadjuvant Chemotherapy for Urothelial Cancer

enthalten in: Clinical genitourinary cancer | 2016

von O'Donnell, P. | Alanee, S. | Stratton, K. | +12